Home › Prostate Cancer › NCT06815354

Comprehensive Assessment of Cancer Theranostic Response

Comprehensive Assessment of Cancer Theranostic Response; Investigating the Intent to Change Treatment Decisions Based on TRAQinform Theranostics

Who can join

Ages 18 and older · Men

Inclusion Criteria:

* Age 18 years or older and willing and able to provide informed consent.
* Diagnosis of metastatic prostate cancer.
* Planned to start 177Lu-PSMA (Pluvicto).
* Ability to tolerate two 68Ga-PSMA or 18F-DCFPyL PET/CT imaging procedures. One at baseline and at 12 weeks of 177Lu-PSMA (Pluvicto) treatment.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at screening.

Exclusion Criteria:

* Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial.

About the study

The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.

What is being tested

• TRAQinform Theranostics (device)

Sponsor: AIQ Solutions · Participants: 32 · Started: Dec 2, 2024

Contact the study team

• Dona Alberti, RN, MSN · Phone: 608-268-9684
• Tim Perk, PhD · Phone: 608-268-9684

Official record on ClinicalTrials.gov — NCT06815354

Locations in the U.S.

Conditions

• Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.